Loading...

Pherecydes Pharma SA

ALPHE.PAEURONEXT
Healthcare
Biotechnology
2.00
-0.01(-0.50%)

Pherecydes Pharma SA (ALPHE.PA) Stock Competitors & Peer Comparison

See (ALPHE.PA) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ALPHE.PA€2.00-0.50%15.8M-2.67-€0.75N/A
UCB.BR€178.15-0.42%33.9B32.57€5.47+0.67%
ARGX.BR€504.00+2.02%30.8B36.08€13.97N/A
TUB.BR€142.40-0.70%6.3B70.50€2.02+0.63%
ABVX.PA€57.00-2.23%3.6B-19.32-€2.95N/A
GLPG.AS€27.20+6.58%1.8B-6.21-€4.38N/A
ALNEV.PA€1.52-7.59%805M-0.01-€221.36N/A
GTBP.PA€280.50+0.00%626.7M-4.10-€68.39N/A
PHARM.AS€0.86-0.46%589.9M-43.05-€0.02N/A
MEDCL.PA€17.11+1.78%566M-15.70-€1.09N/A
Showing 1 to 10 of 69 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ALPHE.PA vs UCB.BR Comparison July 2025

ALPHE.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALPHE.PA stands at 15.8M. In comparison, UCB.BR has a market cap of 33.9B. Regarding current trading prices, ALPHE.PA is priced at €2.00, while UCB.BR trades at €178.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALPHE.PA currently has a P/E ratio of -2.67, whereas UCB.BR's P/E ratio is 32.57. In terms of profitability, ALPHE.PA's ROE is -0.64%, compared to UCB.BR's ROE of +0.11%. Regarding short-term risk, ALPHE.PA is more volatile compared to UCB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHE.PA.Check UCB.BR's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;